Dr. Mehta on the Role of Biomarkers in Gastric Cancer

Rutika J. Mehta, MD, MPH, discusses the role of biomarkers in gastric cancer.

Rutika J. Mehta, MD, MPH, a medical oncologist specializing in gastrointestinal cancer at Moffitt Cancer Center, discusses the role of biomarkers in gastric cancer.

Biomarkers such as microsatellite instability, mismatch repair ​deficiency, HER2 status, PD-L1 ​status, and tumor mutational burden are of interest in the gastric cancer space, says Mehta.

​Moreover, according to Mehta, all patients ​with metastatic disease should be ​molecularly profiled. 

​Additionally, if tissue is available, ordering next​-generation sequencing may be beneficial ​in terms of treatment selection and identifying available clinical trials, Mehta concludes. 

Related Videos
David Samuel Dicapua Siegel, MD
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
 Philip McCarthy, MD
Lova L. Sun, MD, MSCE
Robert M. Rifkin, MD, FACP
Ahmad Tarhini, MD, PhD
Allison Winter, MD
Rocio Garcia-Carbonero, MD
Andrew Ip, MD
Anthony B. El-Khoueiry, MD